Diabetes
17 videos · last 6 months shuffled daily, then older videos newest first
▶
1:46:58 From Wellness App to Digital Health Application: Building a Digital Therapeutic in Europe - E5
GCP-Mindset's Beyond Outcomes talks to Vitadio co-founder Lenka Šomvárska about generating clinical evidence, CE marking and the MDR transition for a type 2 diabetes digital therapeutic.
▶
1:03 QWINT-1: Once-Weekly Insulin Efsitora in Type 2 Diabetes
WeTrials summarises the Phase 3 QWINT-1 trial behind the FDA approval of once-weekly insulin efsitora for type 2 diabetes, in which 795 adults saw A1C fall by a similar amount to daily insulin glargine over 52 weeks.
▶
53:00 The Future of Diabetes Treatment: Beta Cell Regeneration
Michael G. King of Rodman & Renshaw talks to endocrinologist Dr. Alex Abitbol about beta cell regeneration and the evolving diabetes treatment landscape.
▶
5:22 TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity
New Phase 3 TRIUMPH-2 data suggest retatrutide produces substantial weight loss alongside glycemic improvement in people with type 2 diabetes.
▶
10:37 The Evidence Suggesting GLP-1s Can Curb Drug and Alcohol Cravings
PBS NewsHour's William Brangham reports on researchers testing whether GLP-1 drugs can curb people's cravings for drugs and alcohol.
▶
13:06 Lipodystrophy Research Presented at ENDO 2026
Elif Oral, MD, of the University of Michigan reviews lipodystrophy research presented at ENDO 2026, including long-term metreleptin data and baseline results from the METRE-PL Phase 3 trial.
▶
3:04 Mobile Health App Study in Youth With Prediabetes
Talia Hitt, a pediatric endocrinologist at Johns Hopkins Children's Center, discusses her study in which participants aged 13 to 17 with prediabetes used the Prosper mobile health app for lifestyle modification.
▶
52:06 The Latest Therapeutic Developments for Type 1 Diabetes Post-ADA
Piper Sandler analyst Ted Tenthoff and Joslin Diabetes Center's Dr. Rohit Kulkarni discuss type 1 diabetes data from ADA 2026, including teplizumab, beta cell regeneration and menin inhibition.
▶
1:00:00 Arterial Health Biomarkers in Drug Development
A Cardiex webinar explains how a wearable device measuring central blood pressure and pulse wave analysis can provide arterial-stiffness biomarkers and remote real-world evidence for drug development and cardiovascular trials.
▶
6:19 Stanford Diabetes Research Center Employee Discusses How to Get Involved In Diabetes Clinical Research
Stanford University Diabetes Researcher discusses observational studies and interventional trials and why people should participate in clinical trials along with a link to a list of all of the Diabetes clinical trials at Stanford and description of how their online patient screener works.
▶
21:22 Lilla Lördag – Diamyd Medical
Ulf Hannelius, CEO of Diamyd Medical, on precision immunotherapies targeting the autoimmune process behind type 1 diabetes, and the Phase 3 trial of retogatein ahead of a March 2026 interim readout.
▶
1:05:09 Oral Insulin's Journey, Part 2: Hershko and Kidron
Nobel laureate Avram Hershko and Miriam Kidron, chief scientific officer and founder of Oramed Pharmaceuticals, discuss the development of oral insulin ORMD-0801 from concept to a Phase 3 candidate.
▶
3:27 Diabetes Research Institute on One Year Insulin-Free After an Islet Cell Transplant
Marlaina Goedel took part in a Diabetes Research Institute trial testing pancreatic islet cell transplants alongside anti-CD40 ligand, a newer anti-rejection drug. A year on she is living without insulin.
▶
59:14 Oral Insulin ORMD-0801 in Type 2 Diabetes: Expert Webinar
Anne Peters of Keck School of Medicine of USC and former FDA official Alexander Fleming discuss the type 2 diabetes treatment landscape and ORMD-0801, Oramed's oral insulin candidate in Phase 3 trials.
▶
1:48 Stem Cell Clinical Trials for Type 1 Diabetes Breakthrough
A clinical trial was funded by JDRF, a non profit involved in Type 1 Diabetes.
▶
2:11 Clinical Trial Looks at Type 2 Diabetes as an Indicator for Pancreatic Cancer
A clinical trial sponsored by Bluestar Genomics is underway in Palm Beach, Florida and is looking for patients recently diagnosed with Type 2 Diabetes to see if Type 2 Diabetes can be used as an indicator and way of detecting pancreatic cancer in its early stages.
▶
1:01:28 Oral Insulin's Journey, Part 1: Nadav Kidron
Nadav Kidron, CEO of Oramed Pharmaceuticals, traces the development of the company's oral insulin, ORMD-0801, from concept to a Phase 3 candidate in the US.